Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Autor: Kasbekar M; Department of Medicine and., Nardi V; Department of Pathology, Massachusetts General Hospital, Boston, MA., Dal Cin P; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Brunner AM; Massachusetts General Hospital Cancer Center, Boston, MA., Burke M; Massachusetts General Hospital Cancer Center, Boston, MA., Chen YB; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA., Connolly C; Massachusetts General Hospital Cancer Center, Boston, MA., Fathi AT; Massachusetts General Hospital Cancer Center, Boston, MA., Foster J; Massachusetts General Hospital Cancer Center, Boston, MA., Macrae M; Massachusetts General Hospital Cancer Center, Boston, MA., McAfee SL; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA., McGregor K; Cancer Center, Newton-Wellesley Hospital, Newton, MA; and., Narayan R; Massachusetts General Hospital Cancer Center, Boston, MA., Ramos AY; Massachusetts General Hospital Cancer Center, Boston, MA., Som TT; Massachusetts General Hospital Cancer Center, Boston, MA., Vartanian M; Massachusetts General Hospital Cancer Center, Boston, MA., Friedman RS; Cancer Center, Newton-Wellesley Hospital, Newton, MA; and., Benhadji KA; Taiho Oncology, Princeton, NJ., Hobbs GS; Massachusetts General Hospital Cancer Center, Boston, MA.

Publikováno v: Blood advances [Blood Adv] 2020 Jul 14; Vol. 4 (13), pp. 3136-3140.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Autor: Brunner AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Blonquist TM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., DeAngelo DJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., McMasters M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Fell G; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Hermance NM; Department of Biology, Worcester Polytechnic Institute, Worcester, MA, USA., Winer ES; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lindsley RC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Hobbs GS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Amrein PC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Hock HR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Steensma DP; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Garcia JS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Luskin MR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Stone RM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ballen KK; Division of Hematology-Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA., Rosenblatt J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Nahas MR; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Mendez LM; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., McAfee SL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Moran JA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bergeron M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Foster J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bertoli C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Manning AL; Department of Biology, Worcester Polytechnic Institute, Worcester, MA, USA., McGregor KL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fishman KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Kuo FC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Baltay MT; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Macrae M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Burke M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Behnan T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Wey MC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Som TT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ramos AY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Rae J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Lombardi Story J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Nelson N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Logan E; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Connolly C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Neuberg DS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chen YB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Graubert TA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fathi AT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: afathi@partners.org.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2020 Feb; Vol. 7 (2), pp. e122-e133. Date of Electronic Publication: 2019 Dec 11.

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Autor: Fathi AT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA afathi@partners.org., Wander SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Blonquist TM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Brunner AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Amrein PC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Supko J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Hermance NM; Worcester Polytechnic Institute, Department of Biology, Worcester, MA, USA., Manning AL; Worcester Polytechnic Institute, Department of Biology, Worcester, MA, USA., Sadrzadeh H; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Ballen KK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Attar EC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Graubert TA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Hobbs G; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Joseph C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Perry AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Burke M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Silver R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Foster J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Bergeron M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Ramos AY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Som TT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Fishman KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., McGregor KL; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Connolly C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Neuberg DS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Chen YB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.

Publikováno v: Haematologica [Haematologica] 2017 Apr; Vol. 102 (4), pp. 719-727. Date of Electronic Publication: 2016 Dec 29.